Bank Of America Corp Atai Life Sciences N.V. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Bank Of America Corp holds 125,544 shares of ATAI stock, worth $135,587. This represents 0.0% of its overall portfolio holdings.

Number of Shares

125,544

Previous 82,541 52.1%

Holding current value

$135,587

Previous $162,000 2.47%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.27 - $2.6 $54,613 - $111,807	43,003 Added 52.1%	125,544 $166,000
Q1 2024 May 15, 2024	SELL	$1.5 - $2.19 $714,144 - $1.04 Million	-476,096 Reduced 85.22%	82,541 $162,000
Q4 2023 Feb 14, 2024	SELL	$1.04 - $1.55 $2,987 - $4,453	-2,873 Reduced 0.51%	558,637 $787,000
Q2 2023 Aug 14, 2023	SELL	$1.44 - $2.19 $30,360 - $46,173	-21,084 Reduced 3.62%	561,510 $965,000
Q1 2023 May 12, 2023	BUY	$1.17 - $2.7 $573,331 - $1.32 Million	490,027 Added 529.38%	582,594 $1.05 Million
Q4 2022 Feb 10, 2023	SELL	$2.38 - $3.55 $16,093 - $24,005	-6,762 Reduced 6.81%	92,567 $246,000
Q3 2022 Nov 14, 2022	SELL	$3.14 - $4.87 $9,624 - $14,926	-3,065 Reduced 2.99%	99,329 $330,000
Q2 2022 Aug 12, 2022	BUY	$3.03 - $5.32 $30,339 - $53,269	10,013 Added 10.84%	102,394 $372,000
Q1 2022 May 16, 2022	SELL	$4.66 - $7.66 $63,077 - $103,685	-13,536 Reduced 12.78%	92,381 $470,000
Q4 2021 Feb 08, 2022	BUY	$6.82 - $17.8 $578,056 - $1.51 Million	84,759 Added 400.6%	105,917 $808,000
Q3 2021 Nov 15, 2021	BUY	$13.62 - $19.48 $286,128 - $409,235	21,008 Added 14005.33%	21,158 $313,000
Q2 2021 Sep 13, 2021	BUY	$16.94 - $19.89 $2,541 - $2,983	150 New	150 $3,000

Others Institutions Holding ATAI

# of Institutions

Shares Held

12.8M

Call Options Held

9.2K

Put Options Held

118K

View Full List

About ATAI Life Sciences N.V.

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $179M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

More about ATAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Atai Life Sciences N.V. Transaction History